The search for effective COVID-19 management strategies con tinues to evolve. Severity of COVID-19 has been reported to be positively correlated with a concomitant rise in inflammatory cytokine levels (1, 2). Statins (3-hydroxy-3-methylglutaryl co enzyme A (HMG-CoA) reductase inhibitors) are widely used for dyslipidemia for primary and secondary prevention of cardiac and cerebrovascular events. Statins also have anti-inflammatory ef fects, including reducing C-reactive protein (CRP), tumor necrosis factor alpha (TNF-α), interferon gamma (IFNγ) which has been hypothesized in reducing the severity of COVID-19. In this study, we aimed to assess the effects of statin on the length of hospital stay and clinical outcome in patients with COVID-19.